Ozempic Gastroparesis Settlement: Understanding the Statute of Limitations in North Carolina

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Information to Targeted Drug Risk Awareness

This site has long served as a curated resource for those seeking timely, practical information on diet, food, and health. Visitors have relied on frequently updated content to navigate the broad landscape of wellness, from nutritional choices to general health maintenance. The goal has always been to provide clear, accessible guidance without venturing into specialized clinical territory. As the public conversation around health evolves, so too does the need to address emerging concerns that intersect with everyday wellness. One such area involves the growing awareness of pharmaceutical exposures and their potential long-term effects. In particular, the medication Ozempic has become widely discussed, not only for its intended use but also for reports linking it to gastrointestinal complications, including gastroparesis. This shift in focus—from general health information to specific drug-related risks—reflects a natural progression in how individuals seek to understand the products they use. For those in North Carolina who have used Ozempic and are now facing health challenges, questions about legal recourse have arisen. Understanding the statute of limitations for filing a claim related to Ozempic and gastroparesis is a critical step.

Clinical and Pharmacological Context of Ozempic and Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for chronic weight management. Among the adverse effects associated with its use, gastrointestinal complications are prominent, and a growing body of clinical reports and mechanistic understanding has raised concerns about a potential link between Ozempic and gastroparesis—a condition characterized by delayed gastric emptying in the absence of mechanical obstruction. For patients in North Carolina who have developed gastroparesis after using Ozempic, understanding the clinical presentation, pharmacological mechanisms, and legal considerations—including the statute of limitations—is essential. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves a history of these symptoms and objective evidence of delayed gastric emptying, often via gastric emptying scintigraphy. The condition can significantly impair quality of life and lead to nutritional deficiencies, weight loss, and metabolic disturbances. In the context of Ozempic use, patients may experience worsening or new-onset symptoms that mimic or exacerbate underlying gastrointestinal disorders.

Ozempic Pharmacology and Reported Adverse Effects

Ozempic works by mimicking the action of GLP-1, a hormone that stimulates insulin secretion, suppresses glucagon release, and slows gastric emptying. This latter effect is integral to its therapeutic action but also underlies many gastrointestinal adverse reactions. According to the FDA-approved labeling, in placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) versus Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the slowing of gastric emptying is a known pharmacological effect of GLP-1 agonists, and severe or persistent cases may meet diagnostic criteria for gastroparesis.

Mechanistic Pathways Linking Ozempic to Gastroparesis

The primary mechanism by which Ozempic may contribute to gastroparesis is through its action on GLP-1 receptors in the gastrointestinal tract. GLP-1 receptor activation inhibits gastric motility and delays gastric emptying, which is beneficial for glycemic control but can become pathological in susceptible individuals. Chronic use may lead to sustained impairment of gastric peristalsis, potentially resulting in gastroparesis. Additionally, the drug's effects on the autonomic nervous system and enteric neurons may exacerbate pre-existing motility disorders. The dose-dependent increase in gastrointestinal adverse reactions supports a causal relationship, with higher doses (e.g., 2 mg) associated with a greater incidence of such events (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Adequacy of Warnings and Legal Considerations in North Carolina

The current FDA-approved labeling for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis. The label notes that serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported, and caution is advised in patients with a history of such reactions to other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be considered inadequate by some plaintiffs, particularly if patients developed severe, persistent symptoms that were not clearly communicated as potential risks. The adequacy of warnings is a key factor in product liability claims, as manufacturers have a duty to provide sufficient information about known or foreseeable risks. For patients in North Carolina who have developed gastroparesis after using Ozempic, potential settlement considerations include the strength of the causal link, the severity of harm, and the timeline between exposure and documented harm. The evidence from clinical trials shows a clear dose-response relationship for gastrointestinal adverse reactions, which may support claims that Ozempic contributed to or caused gastroparesis. However, individual cases require careful documentation of symptom onset, duration, and objective diagnostic findings. Settlement amounts may vary based on medical expenses, lost wages, pain and suffering, and the degree of manufacturer liability.

Statute of Limitations for Ozempic Claims in North Carolina

The timeline between starting Ozempic and developing gastroparesis is critical for both medical and legal purposes. In clinical trials, gastrointestinal adverse reactions often occurred during dose escalation, suggesting that symptoms may appear within weeks to months of initiation. For patients who develop chronic gastroparesis, the harm may be documented through gastric emptying studies performed after symptom onset. In North Carolina, the statute of limitations for personal injury claims, including product liability, is generally three years from the date the injury was discovered or should have been discovered. This means that affected patients must file a claim within three years of recognizing that their gastroparesis was likely caused by Ozempic. Delays in diagnosis or failure to connect symptoms to the medication could affect the timeline, so prompt medical evaluation and legal consultation are advisable.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for filing an Ozempic gastroparesis claim in North Carolina?

In North Carolina, the statute of limitations for personal injury claims, including product liability, is generally three years from the date the injury was discovered or should have been discovered. For Ozempic-related gastroparesis, this means you must file a claim within three years of recognizing that your condition was likely caused by the medication.

Does the FDA label for Ozempic warn about gastroparesis?

The current FDA-approved labeling for Ozempic includes warnings about gastrointestinal adverse reactions but does not specifically mention gastroparesis. The label notes that serious hypersensitivity reactions have been reported, but the absence of a specific gastroparesis warning may be considered inadequate by some plaintiffs (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Ozempic Labeling

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.